Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Ryan Taggett advises biopharmaceutical and medical device companies across the full range of transactions that arise during the life cycle of a product, including major collaborations, licensing arrangements, clinical trial agreements, and a variety of commercial agreements. He counsels clients ranging from early-stage ventures to large public and private companies on all aspects of transactional matters.

Mr. Taggett's experience includes agreements involving drug discovery, research and development, clinical trials, licensing of development stage and approved products, manufacturing and supply, marketing and co-promotion, technology transfers, consulting and services agreements.

  • Represented a U.S.-based pharmaceutical company in its collaboration agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's and other neurodegenerative diseases.
  • Represented IFM Tre, Inc. in its sale to Novartis for a $310 million upfront cash payment and up to $1.265 billion in milestone payments (for a total of $1.575 billion).
  • Represented a medical device company in its acquisition of ex-U.S. commercialization and development rights to a pain management medical device and software.
  • Represented a major Japanese biopharmaceutical in its exclusive out-license of commercialization and development rights to two neurology and two oncology products for the Latin American markets.
  • Represented a global pharmaceutical company in its in-license to develop and commercialize new drugs in the field of immuno-oncology.
  • Represents various life sciences companies in co-marketing and co-promotion arrangements with peer companies.
  • Represents clinical-stage companies on the establishment of multi-site, international clinical studies for a range of drug products and devices.